P-103

泊沙康唑标准液 溶液

2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

• 經驗公式（希爾表示法）: C₃₇H₄₂F₂N₈O₄
• CAS號碼: 171228-49-2
• 分子量：: 700.78
• EC號碼: 200-659-6
• MDL號碼: MFCD00941162
• 分類程式碼代碼: 41116107
• NACRES: NA.24

屬性

• 等級: certified reference material
• 品質等級: 300
• 形狀: liquid
• 特點: (Snap-N-Spike^®)
• 包裝: ampule of 1 mL
• 製造商／商標名: Cerilliant^®
• 濃度: 2.0 mg/mL in methanol
• 技術: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• 應用: clinical testing
• 格式: single component solution
• 儲存溫度: room temp
• InChI: 1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1
• InChI 密鑰: RAGOYPUPXAKGKH-XAKZXMRKSA-N

描述

一般說明

经认证的Snap-N-Spike^®溶液，适用于通过LC-MS/MS或HPLC在患者血液、血清或血浆样品的泊沙康唑治疗药物监测或临床和诊断测试应用中作为校准品、对照品或线性标准品的起始材料。泊沙康唑以商品名Noxafil^®和Posanol出售，是一种三唑类抗真菌药，用于治疗严重免疫功能低下患者的侵袭性真菌感染。

應用

• Pharmacokinetic modeling in pediatric patients: Posaconazole intravenous solution and oral powder suspension formulations are studied for their pharmacokinetics in pediatric patients with neutropenia, highlighting the solution′s role in optimizing dosing regimens (Winchell et al., 2024).


• Enhanced solubility and bioavailability: Posaconazole antifungal solution is utilized in the development of amorphous solid dispersions with poly(vinylpyridine-co-vinylpyridine N-oxide) excipients, which mediate rapid dissolution and sustained supersaturation, improving its therapeutic efficacy (Liu et al., 2024).


• Nanoformulation for oral delivery: A posaconazole-loaded phospholipid-based nanoformulation developed through design of experiments, machine learning, and TOPSIS optimizes oral delivery, enhancing the antifungal′s absorption and therapeutic profile (Bayat et al., 2024).


• Cost-utility analysis in fungal prophylaxis: Research on posaconazole solution′s cost-effectiveness in preventing invasive fungal infections among leukemia patients undergoing chemotherapy underscores its potential economic benefits in healthcare settings (Pungprasert et al., 2024).


• Cerebrospinal fluid concentrations: Studies assessing the concentrations of posaconazole in cerebrospinal fluid of pediatric leukemia patients validate the solution′s penetration and potential effectiveness in treating central nervous system infections (Körholz et al., 2024).

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Noxafil is a registered trademark of MSD

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

安全資訊

• 象形圖: GHS02,GHS06,GHS08
• 訊號詞: Danger
• 危險聲明: H225,H301 + H311 + H331,H370
• 防範說明: P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311
• 危險分類: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• 標靶器官: Eyes,Central nervous system
• 儲存類別代碼: 3 - Flammable liquids
• 水污染物質分類（WGK）: WGK 2
• 閃點（°F）: 49.5 °F
• 閃點（°C）: 9.7 °C